viernes, 29 de marzo de 2019

Press Announcements > FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism

Press Announcements > FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism



FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism 

The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. Jatenzo should not be used to treat men with “age-related hypogonadism,” in which testosterone levels decline due to aging, even if these men have symptoms that 


No hay comentarios:

Publicar un comentario